glp1medication.guide

glp1 and

GLP-1 and Creatine: Does It Help Preserve Muscle?

What this page establishes

  • Creatine's established effects on strength and lean mass come from resistance-training literature in populations not taking GLP-1s.
  • Creatine supplementation raises intracellular water, which increases scale weight and DXA lean soft tissue independently of contractile tissue change.
  • FDA labelling advises monitoring renal function in GLP-1 patients with GI reactions that could cause dehydration, which is the test creatine confounds.

Quick answers

  • Will it make me look puffy?

    The water it draws is intracellular, meaning it goes into muscle cells rather than sitting under the skin.

    Read the full answer
    That is where the one to two kilograms on the scale comes from. The scale registers it and the mirror generally does not.

  • Will it help with the tiredness or the cramps?

    Nothing here addresses either. What creatine is described as doing is buffering ATP resynthesis for short, high-intensity efforts, which is a training effect rather than a general energy one.

    Read the full answer
    Cramps have their own page at muscle cramps.

  • If it inflates both the scale and my DXA, how do I tell whether I'm keeping muscle?

    After the fact, you largely cannot. Scale weight and DXA lean soft tissue both include the water creatine adds, so they move together for a reason that has nothing to do with contractile tissue.

    Read the full answer
    A scan taken before starting is the only clean baseline available, which is an argument about the order you do things in rather than a reason to skip either.

No randomised trial has tested creatine supplementation in people taking GLP-1 receptor agonists, so the honest answer to whether it preserves muscle on these drugs is that nobody has looked. Creatine's own evidence base in resistance training is solid, and extrapolating it here is reasonable rather than proven. Two artefacts are worth knowing before you start, because both will confuse the numbers you are watching. Creatine adds one to two kilograms of intracellular water to the scale, and it raises measured serum creatinine without any kidney injury, on a drug class whose labelling directs renal monitoring after GI illness.

Is there any GLP-1-specific creatine evidence?

None. No randomised trial has tested creatine supplementation in people taking these drugs, and no observational cohort has reported on it either. Everything below is either creatine's general literature or mechanistic reasoning.

That is worth being blunt about, because creatine is heavily marketed into this exact audience. The claim that it protects muscle on a GLP-1 is an extrapolation from a different population under different conditions.

Extrapolation, not evidence Creatine's established effects on strength and lean mass come from resistance-training literature in people not taking GLP-1s. Nothing has tested whether those effects hold during pharmacological weight loss.

What creatine does independent of any drug

Creatine monohydrate increases muscle phosphocreatine stores, which buffer ATP resynthesis during short, high-intensity efforts. The practical effect is a little more work per session: an extra rep or two at a given load, repeated across months.

That extra training volume is the main route by which creatine contributes to strength and lean mass over time. It is a training amplifier rather than an anabolic agent, which matters for the question being asked here. If the training is not happening, there is not much for it to amplify.

The intracellular water gain and what it does to the scale

Creatine draws water into muscle cells osmotically, adding roughly one to two kilograms of scale weight in the first weeks. That is not fat and it is not contractile tissue.

On a GLP-1, weight is the number everyone is watching, often weekly. Starting creatine in the middle of that produces a stall or a gain that has nothing to do with the drug's effect, at a point where people are most likely to conclude the medication has stopped working. It also inflates DXA lean soft tissue, because lean soft tissue includes water, so it will make a body composition scan look better than the underlying tissue change warrants.

Expect a scale bump One to two kilograms of intracellular water arrives in the first few weeks. If you start creatine, start it at a point where a stalled scale will not be misread, and note the date.

Creatine and serum creatinine on a kidney panel

Creatine is metabolised to creatinine, and creatinine is the analyte used to estimate kidney function. Supplementation therefore raises measured serum creatinine and lowers estimated GFR without any change in kidney health. This is a well-described testing artefact.

The reason it matters more here than elsewhere is the context. FDA labelling advises monitoring renal function in GLP-1 patients with GI reactions that could cause dehydration, because the labelled harm pathway runs from vomiting or diarrhoea to dehydration to acute kidney injury. A creatine-inflated creatinine result taken after a rough week can look exactly like that risk materialising. Tell whoever orders the test that you take creatine, before the blood is drawn.

Hydration considerations

Creatine requires adequate hydration to do its job, and it is being taken on a class where fluid intake is already commonly reduced. A large share of daily water comes from food, and food volume has fallen.

There is no evidence that creatine causes dehydration or increases kidney risk in healthy people. The point is narrower: it adds a requirement to a situation where the supply side has already dropped, and it does so in a population the labelling already flags for dehydration-related harm.

Tolerability when the stomach is already slow

Creatine powder is usually taken in a large volume of fluid, which is the specific thing that is hard when gastric emptying is delayed. Five grams in 500 ml lands badly on a stomach that is still holding breakfast.

GI upset from creatine is dose-related and volume-related in general use, and loading protocols make it worse. Tolerance varies, and there is no GLP-1-specific data on any of this.

So is it worth taking?

The case for is that lean mass loss is real on this class, running roughly 25 to 40% of weight lost in trials without structured training, and creatine has a good general safety record and cheap upside if you are lifting.

The case against is that it has not been tested here, and it degrades two of the measurements you are relying on. Neither of those is a reason not to take it. Both are reasons to know what you are looking at when the scale and the bloods come back.

When to contact a clinician

Only one of these is about creatine causing harm. The others are about creatine confusing the picture.

  • A rising creatinine or falling eGFR result that was interpreted without anyone knowing you take creatine. Tell your clinician and ask whether the result needs repeating.
  • Known kidney disease, where starting creatine needs clinician sign-off rather than a general page.
  • Cramps or dehydration symptoms while supplementing, particularly after a period of vomiting or diarrhoea.
  • Persistent GI upset after starting, which is worth separating from the drug's own effects.
This is general information This page is educational and is not medical advice. Whether creatine is appropriate for you, particularly with any kidney issue, is a clinician's determination.

The evidence, one row per claim

ClaimTierSource
No randomised trial has tested creatine supplementation in people taking GLP-1 receptor agonists.anecdotalunsourced
Creatine's established effects on strength and lean mass come from resistance-training literature in populations not taking GLP-1s.establishedResistance training supplementation meta-analysis context (PMC)
Creatine supplementation raises intracellular water, which increases scale weight and DXA lean soft tissue independently of contractile tissue change.establishedPMC review noting lean soft tissue includes water
Creatine supplementation raises serum creatinine without indicating kidney injury, which can confound the renal monitoring the GLP-1 labels advise.anecdotalunsourced
FDA labelling advises monitoring renal function in GLP-1 patients with GI reactions that could cause dehydration, which is the test creatine confounds.establishedOZEMPIC US Prescribing Information, FDA

Sources

  1. Resistance training supplementation meta-analysis context (PMC)
  2. PMC review noting lean soft tissue includes water
  3. OZEMPIC US Prescribing Information, FDA

Where this comes from

Every number on this page traces to a named source. There are 5 sourced claims below the fold, each with the document it came from.

Sources consulted: unsourced, Resistance training supplementation meta-analysis context, PMC review noting lean soft tissue includes water, OZEMPIC US Prescribing Information.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.

Evidence updates

When a number here changes, you will know